Attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive ADHD

Postgraduate Medicine

Volumn 126, Issue 5, 2014, Pages 7-16

  Manor, Iris ^a   Rubin, Jonathan ^b   Daniely, Yaron ^c   Adler, Lenard A ^d  

^a GEHA MENTAL HEALTH CENTER   (Israel)

^b Alcobra Inc   (United States)

^c Alcobra Ltd   (Israel)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognition; Continuous performance test; Executive function; MDX; Nonstimulant

Indexed keywords

CENTRAL STIMULANT AGENT; DELAYED RELEASE FORMULATION; DRUG COMBINATION; METADOXINE; PYRIDOXINE; PYROGLUTAMIC ACID;

ADOLESCENT; ADULT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; EXECUTIVE FUNCTION; FEMALE; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDOXINE; PYRROLIDONECARBOXYLIC ACID; YOUNG ADULT;

EID: 84921780605     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.09.2795     Document Type: Article

References (44)

1. Wilens TE, Faraone SV, Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA. 2004;292(5):619-623.
2. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder [published correction appears in Lancet. 2006;367(9506):210]. Lancet. 2005;366(9481):237-248.
3. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159-165.
4. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA: American Psychiatric Publishing; 2013.
6. Adler LA, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):187-201.
7. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010;10:67.
8. Greydanus DE, Pratt HD, Patel DR. Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult. Dis Mon. 2007;53(2):70-131.
9. Kessler RC, Green JG, Adler LA, et al. Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale. Arch Gen Psychiatry. 2010;67(11):1168-1178.
10. Biederman J, Petty CR, Woodworth KY, Lomedico A, Hyder LL, Faraone SV. Adult outcome of attention-deficit/hyperactivity disorder: a controlled 16-year follow-up study. J Clin Psychiatry. 2012;73(7):941-950.
11. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry.1996;37(6):393-401.
12. Biederman J, Fried R, Monuteaux MC, et al. A laboratory driving simulation for assessment of driving behavior in adults with ADHD: a controlled study. Ann Gen Psychiatry. 2007;6:4.
13. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-120.
14. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625-639.
15. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebocontrolled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(10):981-989.
16. Biederman J, Arnsten AF, Faraone SV, et al. New developments in the treatment of ADHD. J Clin Psychiatry. 2006;67(1):148-159.
17. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2005;66(2):253-259.
18. Adler LA, Nierenberg A. Review of medication adherence in children and adults with ADHD. Postgrad Med. 2010;122(1):184-191.
19. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21-31.
20. Strattera [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
21. Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. J Psychopharmacol. 2014;28(3):204-211.
22. Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29(1):44-50.
23. Leuchter AF, McGough JJ, Korb AS, et al. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project. J Psychiatric Research. 2014;54:11-18.
24. Caballería J, Parés A, Brú C, et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol. 1998;28(1):54-60.
25. Bono G, Sinforiani E, Merlo P, Belloni G, Soldati M, Gelso E. Alcoholic abstinence syndrome: short-term treatment with metadoxine. Int J Clin Pharmacol Res. 1991;11(1):35-40.
26. Shpilenya LS, Muzychenko AP, Gasbarrini G, Addolorato G. Metadoxine in acute alcohol intoxication: a double-blind, randomized, placebocontrolled study. Alcohol Clin Exp Res. 2002;26(3):340-346.
27. Addolorato G, Ancona C, Capristo E, Gasbarrini G. Metadoxine in the treatment of acute and chronic alcoholism: a review. Int J Immunopathol Pharmacol. 2003;16(3):207-214.
28. Rubin J, Daniely Y, Manor I, Schumann J, Cogram P, Adler L. Metadoxine in ADHD and fragile X syndrome: a novel mechanism of action [abstract]. Presented at Society of Biological Psychiatry 69th Annual Scientific Meeting; May 8-10, 2014; New York, NY. Abstract 446.
29. Adler L. Preferential Effects of Metadoxine Extended-Release on Inattentive Subtype ADHD. Symposium presentation 16.3 at the 60th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 19-27, 2013; Orlando, FL.
30. Manor I, Ben-Hayun R, Aharon-Peretz J, et al. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2012;73(12):1517-1523.
31. Manor I, Newcorn JH, Faraone SV, Adler LA. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder. Postgrad Med. 2013;125(4):181-190.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
33. First MB, Williams JBW, Spitzer RL, Gibbon M. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). New York City, NY: Biometrics Research, New York State Psychiatric Institute; 2007.
34. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.
35. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1983.
36. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II (BDI-II). San Antonio, TX: Psychological Corporation; 1996.
37. Greenberg LM. Attention Deficit Disorders and the Test of Variables of Attention (TOVA). http://www.tovatest.com/adhd. Accessed August 21, 2014.
38. Chamberlain SR, Robbins TW, Winder-Rhodes S, et al. Translational approaches to frontostriatal dysfunction in attention-deficit/hyperactivity disorder using a computerized neuropsychological battery. Biol Psychiatry. 2011;69:1192-1203.
39. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD; US Department of Health, Education, and Welfare; 1976.
40. Greenberg LM, Kindschi CL, Dupuy TR, Hughes SJ. TOVA Clinical Manual. Test of Variables of Attention Continuous Performance Test. Los Alamitos, CA: The TOVA Company; 2007. http://mail.uad.com/manuals/ tova_7_3_Clinical_Manual_2007_02_27.pdf. Accessed August 22, 2014.
41. Roth RM, Isquith PK, Gioia GA. Behavior Rating Inventory of Executive Functioning-Adult Version. Lutz, FL: Psychological Assessment Resources, Inc; 2006.
42. Kuntsi J, Pinto R, Price TS, van der Meere JJ, Frazier-Wood AC, Asherson P. The separation of ADHD inattention and hyperactivityimpulsivity symptoms: pathways from genetic effects to cognitive impairments and symptoms. J Abnorm Child Psychol. 2014;42(1):127-136.
43. Braverman ER, Chen AL, Chen TJ, et al. Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia. Neuropsychiatr Dis Treat. 2010;6:681-690.
44. Huang YS, Wang LJ, Chen CK. Long-term neurocognitive effects of methylphenidate in patients with attention deficit hyperactivity disorder, even at drug-free status. BMC Psychiatry. 2012;12:194.